IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Bamco Inc. NY

Bamco Inc. NY increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,005,522 shares of the company's stock after purchasing an additional 82,264 shares during the quarter. IDEXX Laboratories makes up approximately 2.1% of Bamco Inc. NY's portfolio, making the stock its 10th largest position. Bamco Inc. NY owned about 2.45% of IDEXX Laboratories worth $829,163,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. Hurley Capital LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth approximately $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth $38,000. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $3.37 during trading on Thursday, hitting $489.98. 865,589 shares of the company's stock traded hands, compared to its average volume of 648,607. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market cap of $39.71 billion, a PE ratio of 45.92, a PEG ratio of 3.41 and a beta of 1.52. The firm's fifty day moving average price is $421.25 and its 200 day moving average price is $428.89.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the prior year, the firm posted $2.71 EPS. IDEXX Laboratories's quarterly revenue was up 3.6% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a report on Monday, April 14th. Morgan Stanley raised their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday. Finally, StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.